⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Nintedanib (Ofev) (nintedanib) | 加速させる、線維化研究を

Home/Drugs/Nintedanib (Ofev)

Nintedanib (Ofev)

nintedanib

Approved

Sponsor: Boehringer Ingelheim

Indication: IPF / SSc-ILD

Mechanism of Action

Multi-kinase inhibitor targeting VEGFR, FGFR, and PDGFR pathways

Target: VEGFR, FGFR, PDGFR

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT02182154

Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETED

Relevant Publications (PubMed)

No recent publications found for nintedanib.

Validated Models

This drug has been validated in the following preclinical models:

NCT03413176

Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.

Org:Groupe Hospitalier Pitie-Salpetriere

TERMINATEDNCT02231164

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Phase:PHASE3Org:Boehringer Ingelheim

COMPLETEDNCT05483907

To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

Phase:PHASE2Org:Bridge Biotherapeutics, Inc.

TERMINATEDNCT03733444

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Phase:PHASE3Org:Galapagos NV

View all trials on ClinicalTrials.gov